DiaMedica Therapeutics (DMAC) Enterprise Value (2017 - 2026)

DiaMedica Therapeutics' Enterprise Value history runs 10 years deep, the most recent figure standing at -$51.3 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 1740.48% year-over-year to -$51.3 million in Q1 2026; TTM through Mar 2026 was -$51.3 million, a 1740.48% decrease from a year earlier, with the FY2025 full-year figure at -$59.9 million, down 35.66% from the prior year.
• Enterprise Value climbed to -$51.3 million in Q1 2026 per DMAC's latest filing, from -$59.9 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$2.8 million in Q3 2022 and bottomed at -$59.9 million in Q4 2025.
• The 5-year median for Enterprise Value is -$44.1 million (2024), against an average of -$36.2 million.
• Across the five-year window, Enterprise Value surged 94.22% in 2022 and tumbled 1740.48% in 2026, its largest moves.
• Year by year, Enterprise Value stood at -$33.5 million in 2022, then plunged by 57.89% to -$52.9 million in 2023, then advanced by 16.54% to -$44.1 million in 2024, then plunged by 35.66% to -$59.9 million in 2025, then grew by 14.29% to -$51.3 million in 2026.
• Per Business Quant, the three latest DMAC Enterprise Value figures stand at -$51.3 million (Q1 2026), -$59.9 million (Q4 2025), and -$55.3 million (Q3 2025).